Abstract
We compared the efficacy of etoricoxib 30
mg to placebo and ibuprofen 2400
mg for the treatment of osteoarthritis (OA) of the hip and knee.
In this 12-week, randomized, double-blind, placebo- and active-comparator-controlled trial, 548 patients (median age 63 years) with OA of the hip or knee were randomized to receive placebo, etoricoxib 30
mg q.d., or ibuprofen 800
mg t.i.d. Demonstration of etoricoxib's efficacy vs placebo and comparison of its efficacy to ibuprofen were assessed using three co-primary endpoints: Western Ontario and McMaster's University Osteoarthritis Index (WOMAC) Pain Subscale (WOMAC-PS); WOMAC Physical Function Subscale (WOMAC-PFS); and Patient Global Assessment of Disease Status (PGADS). Each primary endpoint utilizes a 0–100
mm visual analog scale. To demonstrate comparable efficacy of etoricoxib vs ibuprofen, the 95% confidence intervals (CIs) for the difference in the least squares (LS) mean change over 12 weeks for all three co-primary endpoints had to fall within ±10
mm. Safety and tolerability data were collected throughout the study.
Mean baseline values for the three co-primary endpoints ranged from 62.52 to 70.14
mm. Both etoricoxib and ibuprofen demonstrated superior (
P
≤
0.002) efficacy for all primary endpoints. The LS mean (mm) changes (95% CI) over 12 weeks for etoricoxib and ibuprofen, respectively, compared to placebo were given as follows: WOMAC-PS: −11.66 (−16.31, −7.01) and −7.62 (−12.30, −2.94); WOMAC-PFS: −10.15 (−14.74, −5.57) and −7.23 (−11.85, −2.61); PGADS: −11.65 (−16.81, −6.50) and −8.11 (−13.30, −2.92). The efficacy of etoricoxib 30
mg was comparable to ibuprofen 2400
mg. All treatments were similarly well tolerated.
Treatment with etoricoxib 30
mg q.d. provides superior efficacy vs placebo and comparable clinical efficacy vs ibuprofen 2400
mg (800
mg t.i.d.) for the treatment of OA of the hip and knee.
